# Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

> **NCT03457948** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nicholas Fidelman, MD** · enrollment: 32 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Liver
- Neuroendocrine Neoplasm

## Interventions

- **PROCEDURE:** Arterial Embolization
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
- **DEVICE:** Yttrium-90 Microsphere Radioembolization

## Key facts

- **NCT ID:** NCT03457948
- **Lead sponsor:** Nicholas Fidelman, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-27
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-09-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03457948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03457948, "Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03457948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*